TIDMPYC
RNS Number : 9947S
Physiomics PLC
10 November 2023
10 November 2023
Physiomics plc
("Physiomics" or "the Company")
Innovate UK grant award
Physiomics plc (AIM: PYC), a leading mathematical modelling
company, supporting development of oncology drugs and personalised
medicine solutions, is pleased to announce that it has been awarded
a grant by Innovate UK and The Office for Life Sciences as part of
the UK Government's Advancing Precision Medicine programme. The
grant-funded project is called "PREDICT-ONC: Precision Risk
Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia
Tool" (the "Project" or "PREDICT-ONC") and will be carried out in
partnership with Beyond Blood Diagnostics Limited ("Beyond Blood
Diagnostics") and Blackpool Teaching Hospitals NHS Foundation Trust
("Blackpool Teaching Hospitals"). The Project's total costs, shared
between the three partners, are expected be GBP570,651, of which
Physiomics' costs are expected to be GBP196,251 (primarily
comprising staff salaries). The Project costs are 70% funded by the
grant, hence Physiomics will receive GBP137,376 over the course of
the Project which will start immediately and is expected to run
until October 2025.
PREDICT-ONC is designed to generate data to further develop
Physiomics' personalised dosing tool which has been funded by
previous grants, including GBP68,000 awarded by Innovate UK, as
announced in March 2018, and GBP150,000 awarded by the National
Institute for Health and Care Research ("NIHR") to fund the PARTNER
study, as announced March 2020. Focusing on cancers treated with
docetaxel, PREDICT-ONC aims to address unmet clinical need in the
diagnosis and management of chemotherapy induced neutropenia by
extending Physiomics' personalised dosing tool to support clinical
decision-making around G-CSF dosing to optimise therapeutic
outcomes.
PREDICT-ONC will generate data through an observational clinical
trial where patients will be monitored rigorously during their
planned course of chemotherapy to gather data on their neutrophil
counts, G-CSF treatment and drug-related side-effects. The trial
lead investigator will be Prof. Francis Martin, an outstanding
researcher who has led over 60 clinical trials and is the Lead
Manager at the Patient Recruitment Centre ("PRC") at Blackpool
Victoria Teaching Hospitals NHS Foundation Trust. PRC Blackpool is
one of only 5 NIHR-funded PRCs nationally and contributes
significantly to the >100 clinical trials running at Blackpool
Teaching Hospitals NHS Foundation Trust. Prof Martin's team at
Blackpool is also a member of the University of Manchester-led
NIHR-funded Biomedical Research Centre (launched in March 2023).
During the trial, patient blood samples will be taken by
traditional phlebotomy and, in parallel, using Beyond Blood
Diagnostics' miniaturised point of care tool in order to assess and
validate its ability to generate blood diagnostic data in point of
care settings, potentially reducing the need for patients to travel
to hospitals and secondary care centres for these tests. Beyond
Blood Diagnostics will also be analysing data to determine if their
tool can detect other early signs of neutropaenia.
By leveraging the expertise of Physiomics, Beyond Blood
Diagnostics and Blackpool Teaching Hospitals, we believe there is
the potential to develop a solution that could revolutionise the
current approach to neutropenia diagnosis and treatment.
Physiomics CEO, Dr Jim Millen, commented :
"We are delighted to have won our fourth Innovate UK award,
which we believe is a testimony to the innovative culture of our
company. This grant gives us a unique opportunity to capitalise on
previous grant-funded work in the personalised oncology space, as
well as foster our collaboration with Beyond Blood Diagnostics Ltd,
and we are looking forward to working with new partner, Blackpool
Teaching Hospitals NHS Foundation Trust."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics plc
Physiomics plc combines cutting edge PK/PD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 projects, over 50 targets and 75 drugs. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
About Beyond Blood Diagnostics Limited
Beyond Blood Diagnostics Limited is a spinout from Imperial
College London which has already won four Innovate UK grants and
benefits from the backing of a number of leading US and UK DeepTech
investors. Beyond Blood is developing a new technology to detect
and identify various types of blood cells based on their unique
biophysical properties. Beyond Blood's technology leverages
off-the-shelf, low-cost components to enable the creation of a
small-scale device which aims to reproduce the accuracy of
conventional laboratory grade flow cytometers routinely used in
hospitals for diagnosis and to enable a full analysis in under 5
minutes.
About Blackpool Teaching Hospitals NHS Foundation Trust Patient
Recruitment Centre ("PRC")
PRC Blackpool is funded by the NIHR and one of only five in
existence in the UK. Over the last four years the PRC has delivered
a range of studies in many specialty areas, achieving many UK and
world firsts for clinical trials. PRC Blackpool is also a
consortium member of the University of Manchester-led Biomedical
Research Centre ( "BRC" ), which focuses on early clinical
translational research. This is the only BRC outside the South, and
is a GBP60 million research entity launched in March 2023 and
funded by the NIHR for an initial period of five years.
About Innovate UK
Innovate UK is the UK's national innovation agency that aims to
create a better future by inspiring, involving and investing in
businesses developing life-changing innovations.
Innovate UK provides targeted sectors with expertise, facilities
and funding to test, demonstrate and evolve their ideas, driving UK
productivity and economic growth. There is a chance to join
Innovate UK's network and communities of innovators to realise the
potential of your ideas and accelerate business growth.
About The Office for Life Sciences
The Office for Life Sciences ("OLS") is a joint unit between the
Department of Health and Social Care and the Department for
Science, Innovation and Technology. OLS exists to improve the
health and wealth of the nation by growing a resilient and
innovative life sciences sector in the UK, and by bringing new
technologies and treatments into the NHS to transform
healthcare.
OLS funding for the Advancing Precision Medicine programme is
provided as part of the UK Government's Life Science Cancer
Mission. The Cancer Mission aims to make the UK a leading testbed
for oncology innovation by accelerating the development and
commercialisation of a new generation of cancer diagnostics and
therapeutics, allowing patients to be diagnosed earlier and offered
therapies specifically designed to target their cancer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZMGMVLRGFZM
(END) Dow Jones Newswires
November 10, 2023 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
